Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells

British Journal of Dermatology

Volumn 166, Issue 6, 2012, Pages 1349-1352

  Vasiadi, M ^a,b,c   Therianou, A ^c   Alysandratos, K D ^a,c   Katsarou Katsari, A ^c   Petrakopoulou, T ^d   Theoharides, A ^e   Papadavid, E ^c   Stavrianeas, N ^c   Antoniou, C ^c   Kalogeromitros, D ^c   Theoharides, T C ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Oncology Hospital   (Greece)

^e Ano Toumba Polyclinic   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; MESSENGER RNA; NEUROTENSIN; NEUROTENSIN RECEPTOR; VASCULOTROPIN;

ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PSORIASIS; PSORIASIS VULGARIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN DEFECT; STRESS;

ADULT; CELLS, CULTURED; FEMALE; HUMANS; MALE; MAST CELLS; MIDDLE AGED; NEUROTENSIN; PSORIASIS; RECEPTORS, NEUROTENSIN; SKIN; STRESS, PSYCHOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861612149     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10843.x     Document Type: Article

References (16)

1. Gottlieb AB,. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19-34.
2. Saraceno R, Kleyn CE, Terenghi G, et al. The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155: 876-82.
3. Mustain WC, Rychahou PG, Evers BM,. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes 2011; 18: 75-82.
4. Cochrane DE, Boucher W, Bibb P,. Neurotensin stimulates histamine release in in vivo skin 'blisters' in rats: an effect inhibited by cromolyn or somatostatin. Int Arch Allergy Immunol 1986; 80: 225-30.
5. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 2006; 103: 7759-64.
6. Tagen M, Stiles L, Kalogeromitros D, et al. Skin corticotropin-releasing hormone receptor expression in psoriasis. J Invest Dermatol 2007; 127: 1789-91.
7. Feldberg RS, Cochrane DE, Carraway RE, et al. Evidence for a neurotensin receptor in rat serosal mast cells. Inflamm Res 1998; 47: 245-50.
8. Cochrane DE, Carraway RE, Boucher W, et al. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides 1991; 12: 1187-94.
9. Jiang WY, Chattedee AD, Raychaudhuri SP, et al. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001; 40: 699-703.
10. Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25: 563-8.
11. Slominski A, Wortsman J,. Neuroendocrinology of the skin. Endocr Rev 2000; 21: 457-87.
12. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 2010; 107: 4448-53.
13. Amatya B, El-Nour H, Holst M, et al. Expression of tachykinins and their receptors in plaque psoriasis with pruritus. Br J Dermatol 2011; 164: 1023-9.
14. Reich A, Orda A, Wisnicka B, et al. Plasma concentration of selected neuropeptides in patients suffering from psoriasis. Exp Dermatol 2007; 16: 421-8.
15. Metz M, Maurer M,. Innate immunity and allergy in the skin. Curr Opin Immunol 2009; 21: 687-93.
16. Paus R, Theoharides TC, Arck PC,. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 2006; 27: 32-9.